Atezolizumab, Tobemstomig, Tiragolumab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-31 in 3mo
ESTIMATED |
READOUT
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIG
Phase 2 · Urothelial Cancer |
Hoffmann-La Roche | Atezolizumab, Tobemstomig, Tiragolumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|